Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 21, 2020 - Issue 17
Submit an article Journal homepage
2,752
Views
3
CrossRef citations to date
0
Altmetric
Editorial

Is the pharmacological management of bulimia nervosa plausible?

Guido K.W. FrankDepartment of Psychiatry, University of California at San Diego, San Diego, CA, USACorrespondence[email protected]
View further author information
Pages 2073-2075 | Published online: 09 Aug 2020

References

  • American Psychiatric Association., American Psychiatric Association. DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, D.C.: American Psychiatric Association; 2013.
  • Hudson JI, Hiripi E, Pope HG Jr., et al. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007 Feb 01;61(3):348–358.
  • Frank GKW, Berner LA, editors. Binge eating: A transdiagnostic psychopathology. Springer Nature Switzerland; 2020, 321 p.
  • Okon-Singer H, Hendler T, Pessoa L, et al. The neurobiology of emotion-cognition interactions: fundamental questions and strategies for future research. Front Hum Neurosci. 2015;9:58.
  • Logue SF, Gould TJ. The neural and genetic basis of executive function: attention, cognitive flexibility, and response inhibition. Pharmacol Biochem Behav. 2014 Aug;123:45–54.
  • Culbert KM, Racine SE, Klump KL. Hormonal factors and disturbances in eating disorders. Curr Psychiatry Rep. 2016 Jul;18(7):65.
  • Gearhardt AN, Yokum S, Orr PT, et al. Neural correlates of food addiction. Arch Gen Psychiatry. 2011 Aug;68(8):808–816.
  • Frank GK, Reynolds JR, Shott ME, et al. Altered temporal difference learning in bulimia nervosa. Biol Psychiatry. 2011 Oct 15;70(8):728–735.
  • Bohon C, Stice E. Negative affect and neural response to palatable food intake in bulimia nervosa. Appetite. 2012 Jun;58(3):964–970.
  • (FDA) FaDA. Bulimia nervosa prescribing information. 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf
  • Bacaltchuk J, Hay P. Antidepressants versus placebo for people with bulimia nervosa. Cochrane Database Syst Rev. 2003;4:CD003391.
  • Romano SJ, Halmi KA, Sarkar NP, et al. A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am J Psychiatry. 2002 Jan;159(1):96–102.
  • Trunko ME, Schwartz TA, Marzola E, et al. Lamotrigine use in patients with binge eating and purging, significant affect dysregulation, and poor impulse control. Int J Eat Disord. 2014 Apr;47(3):329–334.
  • Guerdjikova AI, McElroy SL. Adjunctive methylphenidate in the treatment of bulimia nervosa co-occurring with bipolar disorder and substance dependence. Innovations in Clinical Neuroscience. 2013 Feb;10(2):30–33.
  • McElroy SL, Guerdjikova AI, Mori N, et al. Progress in developing pharmacologic agents to treat bulimia nervosa. CNS Drugs. 2019 Jan;33(1):31–46.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.